Focal lymphoid aggregates (nodules) in bone marrow biopsies: differentiation between benign hyperplasia and malignant lymphoma—a practical guideline

J Thiele, T K Zirbes, H M Kvasnicka, R Fischer

Abstract

Aims—To provide practical guidelines for the differentiation between benign and malignant focal lymphoid aggregates (lymphoid nodules) in routinely referred bone marrow trephine biopsies, using a synoptic approach including clinical data and histological workup.

Methods—For easy identification of very small lymphoid infiltrates the chloroacetate esterase stain was applied as a screening procedure. This allowed the identification of 491 formalin fixed, paraffin wax embedded specimens with one or more lymphoid nodules. Examination of lymphoid infiltrates included such variables as histotopography, demarcation, cytology, reticulin fibres, and immunohistochemistry with a set of monoclonal antibodies (CD20, CD45R, CD45R0, CD3, CD43). Evaluation of clinical and morphological data was carried out independently. In case of malignant lymphomas, a correlation with corresponding lymph node findings was made.

Results—352 patients had benign focal lymphoid aggregates usually associated with systemic autoimmune diseases, chronic myeloproliferative disorders, toxic myelopathy, and viral infections. Discrete nodular infiltrates of (small cell) malignant lymphomas (n = 93) simulating benign hyperplasia were found in chronic lymphocytic leukaemia, germinal centre cell lymphomas (CB-CC), and lymphoplasmacytic/cytoid lymphomas (LPI). In addition to immunoreactivity, certain histological variables proved distinctive. These were: (1) histotopography, that is, localisation of the lymphoid aggregates within the bone marrow space; (2) relation to the surrounding tissue: margination or interstitial spillage of lymphoid cells; and (3) increase in reticulin fibres.

Conclusions—A combined diagnostic procedure identifying several distinctive features, in particular histotopography and immunohistochemistry, provides a most promising way of discriminating reactive from neoplastic lymphoid nodules in the bone marrow.

(J Clin Pathol 1999;52:294-300)

There is still a conflict of opinion over the distinction between benign (reactive) focal lymphoid aggregates (nodules, hyperplasia) and infiltrates of malignant lymphomas in bone marrow tissue.¹⁻⁶ This is one of the major continuing problems in haematopathology. In daily routine, the pathologist is frequently confronted by focal lymphoid marrow aggregates of uncertain origin. These lesions may be found in samples derived either from patients with a known lymphoproliferative disorder during a primary or secondary staging procedure, or in specimens with the clinical question of malignant lymphoma, though without appropriate lymph node histology. Moreover, controversy may arise over whether extensive lymphoid nodules accompanying chronic myeloproliferative disorders are only a reactive feature.⁷⁻¹⁰ Finally, many focal lymphoid lesions within the bone marrow lack a relation with an established disorder. In the majority of cases these are associated with the rather ill defined finding of anaemia, particularly in a geriatric population.²⁻⁴

Our purpose in this study was to investigate systematically the occurrence and relevance of focal lymphoid aggregates in bone marrow trephine biopsy samples retained from routinely referred material. In a synoptic review of the underlying clinical conditions and marrow features, including in particular histotopography, content of reticulin fibres, and immunohistochemistry, we tried to distinguish between benign lymphoid nodules and focal manifestations of malignant lymphomas of the non-Hodgkin and Hodgkin type.

Methods

PATIENTS AND BONE MARROW BIOPSIES

Selection of bone marrow samples included a three step procedure. First, a review of about 18 000 representative trephine biopsies drawn from our files and stained by naphthol-AS-D-chloroacetate esterase showed more than 491 specimens with one or several prominent lymphoid aggregates of different size, shape, and cytology. Second, these lymphoid nodules were classified into reactive or neoplastic lesions according to histological appearance and results of immunostaining without knowledge of the patient's identity. Third, the diagnosis was reconsidered in a retrospective analysis of the clinical data. In cases of non-Hodgkin and Hodgkin lymphoma, lymph node pathology and bone marrow findings were compared and correlated with the clinical status. High grade

Institute of Pathology,
University of Cologne,
Joseph-Stelzmann-Str
9, 50924 Cologne,
Germany
J Thiele
T K Zirbes
H M Kvasnicka
R Fischer

Correspondence to:
Dr Thiele
email: j.thiele@uni-koeln.de

Accepted for publication
27 November 1998

Keywords: lymphoid nodules; reactive neoplastic lesions; bone marrow; trephine biopsies

Table 1 Monoclonal antibodies according to the CD classification¹⁴ used in the present study

Antibody	CD classification	Reacting cell population	Source
L26	CD 20	B lymphocytes	Dako Diagnostika, Hamburg
4 KB5	CD 45 R	B lymphocytes	Dako Diagnostika, Hamburg
LCA	CD 45	Granulo-lymphocytes	Dako Diagnostika, Hamburg
UCHL-1	CD 45 RO	T lymphocytes and mono-histiocytes	Dako Diagnostika, Hamburg
PC3/188A	CD 3	T lymphocytes and mono-histiocytes	Dako Diagnostika, Hamburg
Ki-1 (Ber H2)	CD 30	Activated lymphoid cells, Reed-Sternberg cells	Dako Diagnostika, Hamburg
MT1	CD 43	T lymphocytes and myeloid cells	Clonab, Dreieich

collaboration was possible because our institution is a lymphoma referral centre. Subtyping of NHL was performed according to the updated Kiel classification.¹¹ Patients apparently showing benign focal lymphoid infiltrates were re-evaluated with respect to their underlying condition.

BIOPSY TECHNIQUES AND HISTOLOGICAL PREPARATION

Following a representative trephine biopsy from the posterior iliac crest, fixation was performed in an aldehyde solution for 12 to 24 hours (2 ml 25% glutaraldehyde, 3 ml 37% formaldehyde, 1.58 g calcium acetate, and distilled water to 100 ml). Further processing included decalcification for three to four days in 10% buffered EDTA pH 7.2–7.4, paraffin embedding, and employment of several staining techniques: Giemsa, PAS (periodic acid Schiff reaction), naphthol-AS-D-chloroacetate esterase, Perl's reaction for iron, and the silver impregnation method after Gomori.¹²

IMMUNOSTAINING

Pretreatment of mounted paraffin sections included dewaxing through xylene and alcohol and rinsing in buffer (50 mM Tris-HCl, pH 7.6) for 30 minutes. Thereafter samples were stained according to the alkaline phosphatase–anti-alkaline phosphatase (APAAP) technique¹³ applying monoclonal antibodies¹⁴ listed in table 1 in proper concentrations (1:50–100) and variable incubation times (30 minutes to one hour), using new fuchsin as the alkaline phosphatase substrate. To demonstrate monoclonal immunoglobulin expression, the peroxidase–antiperoxidase (PAP) method was applied in combination with polyclonal antibodies, as previously described in more detail.¹⁵

Results

The focal lymphoid aggregates found in our bone marrow trephine biopsies varied significantly in frequency, size, localisation, cytological appearance, reticulin fibre content, and immunoreactivity. Features that allowed ready differentiation between benign lymphoid nodules and non-Hodgkin/Hodgkin lymphoma were as follows: first, true lymphoid follicles (fig 1A) with germinal centres cuffing central marrow vessels in 21 patients with an autoimmune disorder (table 2); second, in 46 patients focal accumulations of large blastic (centroblastic–immunoblastic) or polymorphous cells were observed in non-Hodgkin lymphomas of high malignancy; and third, nodular ill defined lesions with increased fibres, vascular proliferation, T lymphocytes, and plasma cells suggested angioimmunoblas-

tic (AILD), while others containing atypical histiocytic cells and mononuclear Hodgkin and Reed-Sternberg cells were consistent with Hodgkin lymphoma (table 3). It should be emphasised that in these cases histopathology was compatible with the diagnosis.

In contrast with those findings, in 93 patients it was difficult to assess solitary or multiple infiltrates (up to eight in one sectional profile) composed of small to intermediate lymphoid cells and simulating benign lymphoid nodules (table 3). The procedures that were especially useful in classifying these were histotopography (localisation and infiltration pattern), demarcation, fibre content, and immunostaining. To reach a correct final diagnosis these features should be considered in a synoptic evaluation, as outlined in more detail in table 4. In this context we should emphasise that every malignant lymphoid infiltrate had a corresponding lymph node diagnosis of lymphoma.

Lymphoid aggregates of reactive origin show a tendency to central localisation and usually have a clearly defined border margin consisting of a mixture of B and T lymphocytes (fig 1, C–F). A superficial/subcortical infiltrate in the age related adipose tissue or an endosteal tapestry-like (paratrabeular) involvement was not detectable in benign lymphoid nodules, but regularly encountered in CB-CC non-Hodgkin lymphoma (figs 1B; 2C–E) and also in several cases of lymphoplasmacytic/cytoid (LPI) non-Hodgkin lymphoma. An ill defined border of a nodular lymphoid aggregate with spillage of single lymphocytes between the adipocytes or an indian-file-like interstitial extension is often recognised in non-Hodgkin lymphoma (figs 2A,B; 3A,B), but never prominent in reactive hyperplasia. This overspill of lymphocytes into internodular areas is can be shown by applying immunohistochemical methods (figs 2B; 3A). A moderate to pronounced increase in reticulin fibre density within the infiltrates is limited to certain subtypes of non-Hodgkin lymphoma such as CB-CC, LPI (figs 2F, 3C), and T cell lymphomas (AILD), in addition to Hodgkin lymphoma. Contrasting with this finding, chronic lymphocytic leukaemia, with a strictly nodular central infiltration pattern, is not characterised by a conspicuous meshwork of reticulin. On the other hand, in HIV myelopathy the inflammatory reaction of the bone marrow stroma is often accompanied by a borderline to moderate increase in fibres. Although the above mentioned indices may be very helpful in distinguishing reactive from neoplastic lymphoid nodules, immunostaining with a set of easy to handle monoclonal antibodies (table 1) presents an invaluable diagnostic tool. This implies first, the demonstration of a uniform

infiltration pattern consisting of B (or rarely T) lymphocytes in accordance with the subtype of NHL (figs 2C–E; 3A,B, D–F); and second, the presence of immunoglobulin light and heavy chain restrictions which proves to be sufficiently reliable to establish monoclonality, as in LPI non-Hodgkin lymphoma (fig 3G, H). For practical purpose a combination of at least two so called B and T cell markers (table 1) is advisable, since most monoclonal antibodies show variable cross reactivity with other myeloid cells (figs 2D,E; 3E,F). Relevant features aiding the differentiation between

benign lymphoid nodules and non-Hodgkin/Hodgkin lymphoma are summarised in table 4.

Finally, when comparing the histological appearance of non-Hodgkin lymphoma in lymph nodes and bone marrow by applying the updated Kiel classification,¹¹ in seven cases a discordance was evident. These disparate subtypes included mostly a CB-CC differentiation pattern in the lymph nodes contrasting with a variable fraction of centrocytes versus centroblasts in the bone marrow, or a lymphocytic non-Hodgkin lymphoma in the marrow versus an LPI in the periphery. Several indetermi-

Figure 1 Follicular lymphoid aggregate (true lymphoid follicle) showing a germinal centre in rheumatoid arthritis (A) versus paratrabeal (endosteal) cuffing of malignant lymphoma (germinal centre cell lymphomas (CB-CC)) detected by AS-D-chloroacetate esterase staining (B). Immunohistochemistry of benign focal lymphoid infiltrates in idiopathic (primary) myelofibrosis (C,D) showing a mixture of B (L26) and T lymphocytes (UCHL-1), in addition to large megakaryocytes (arrowheads). Lymphoid nodule in HIV myelopathy (AIDS) with immunoreactivity revealing a mixture of many T lymphocytes (E) together with a fair number of B lymphocytes (F). (Magnifications: A $\times 175$; B–F $\times 144$.)

Table 2 Benign lymphoid nodules (n=352) and underlying disorders presenting in about 18 000 trephine biopsies of the bone marrow

I. Systemic autoimmune disorders	
(a) Rheumatoid arthritis, lupus erythematosus	52
(b) Autoimmune haemolytic anaemia	38
(c) Idiopathic thrombocytopenia	12
(d) Hyper-/hypothyroidism (Hashimoto)	5
II. Chronic myeloproliferative disorders	
(a) Polycythaemia vera	47
(b) Idiopathic (primary) myelofibrosis	38
(c) Chronic myeloid leukaemia	16
(d) Essential (primary) thrombocythaemia	5
III. Aplastic anaemia (toxic myelopathy)	32
IV. Myelodysplastic syndromes	15
V. Viral infections	
(a) Hepatitis (B and C type)	17
(b) HIV myelopathy (AIDS)	48
VI. Unknown or not evaluable	27

Table 3 Focal bone marrow infiltrates (n=139) in malignant lymphomas: subtypes according to the updated Kiel classification¹¹

Lymphocytic (chronic lymphocytic leukaemia, CLL)	29
Centroblastic-centrocytic (CB-CC)	49
Lymphoplasmacytic/cytoid (LPI)	15
Centroblastic (CB)	12
Immunoblastic (IB)	8
Burkitt type	3
T cell lymphoma (angioimmunoblastic, AILD)	8
Hodgkin lymphoma (HL)	15

ble cases were also encountered. These included reactive lymphoid accumulations in 17 patients, in whom no relevant underlying disorder could be evaluated. More important, however, were foci of centrally localised (perivascular cuffing) small lymphoid cells displaying T and B cell markers in 10 patients following chemotherapy of large cell, highly malignant non-Hodgkin lymphoma (secondary staging procedure). These infiltrates did not correspond with the histological appearance (cytology, histotopography) of the re-evaluated primary lesions and were therefore regarded as reactive in nature.

Discussion

In recent years a wealth of data has accumulated on the clinical importance of making a clear cut distinction between benign lymphoid nodules and focal infiltrations by non-Hodgkin lymphoma^{5 16-22} and Hodgkin lymphoma^{20 21 23} in the bone marrow. Conventional morphological studies may provide clues to the nature of the lymphoid lesions in those cases, where either large blastic or grossly abnormal cells or a so called packed marrow with an extensive growth pattern are observed.^{2 16 17 21 22} Considerable diagnostic difficulties arise, however, when lymphoid cell involvement is strictly focal and composed of small to intermediate sized elements. Infiltrates of this kind may present

early stages of non-Hodgkin lymphoma, especially lymphocytic lymphoma (chronic lymphocytic leukaemia) with a central localisation simulating reactive lesions. In these cases the differentiation has to be unequivocal, because the infiltration pattern of chronic lymphocytic leukaemia has repeatedly been shown to be important in prognosis.^{16 24-28}

In this study, we have emphasised a synoptic approach to these diagnostic problems, including comparative clinical data and an elaborate histological work up of bone marrow trephine biopsies. Particular interest was focused on the histotopography of lymphoid aggregates in combination with immunohistochemical reactions in providing practical guidelines for diagnosis. However, the method of selection needs to be emphasised, because, in contrast with all other studies where routine staining techniques were applied,^{1-5 16-19} we started with the chloroacetate esterase reaction as the primary screening procedure. This selection criterion for case retrieval was chosen to detect even very small lymphoid infiltrates, in particular those adjacent to the bony trabeculae or generation zone of granulopoiesis which otherwise easily escape recognition. The diagnostic impact of the infiltration pattern also needs emphasis, since it included not only the endosteal localisation that indicated malignancy,^{2 5 6 16 21 22} but also subcortical involvement of the superficial age related adipose tissue (table 4). In contrast to the well defined and rather discrete outlines of benign lymphoid nodules, fat cells between questionable infiltrates characterised the interstitial spread or spillage of lymphoid cells and therefore suggested non-Hodgkin lymphoma (figs 2B; 3C). These relations between lymphoid nodules and surrounding bone marrow were most impressively demonstrable by applying enzyme (AS-D-chloroacetate esterase) and immunostaining techniques. Although in HIV myelopathy (AIDS), reactive lymphoid aggregates show an increase in finely dispersed fibres,²⁹⁻³¹ non-Hodgkin lymphomas, with the exception of chronic lymphocytic leukaemia, usually showed a definite tendency to develop a moderate to significant accumulation of reticulin.^{16 32}

A conflict of opinion has emerged over whether monoclonality is definite proof of malignancy, particularly with respect to corresponding bone marrow lesions. It is not universally accepted that an accumulation of plasma cells with (monotypic) light chain restrictions implies malignancy, because not all monoclonal gammopathies are compatible with malignant myelomas. Moreover, there are

Table 4 Criteria for the differentiation between focal infiltrates of malignant lymphomas and reactive nodular lymphoid hyperplasia

Variable	Malignant lymphoma	Benign lymphoid aggregate
Number of infiltrates in section profile	≥1 without germinal centres	≤3 with partial germinal centres (lymphoid follicles)
Histotopography	1. Paratrabeular-endosteal (except CLL) 2. Subcortical in adipose tissue 3. Focal-nodular with interstitial spread (indian file pattern)	1. Central-perivascular 2. Deep marrow spaces 3. Fairly defined margin
Reticulin fibres	Moderate to advanced (except CLL)	Borderline to minimal (except HIV myelopathy)
Immunohistochemistry	Uniform pattern with predominance of B or T lymphocytes; expression of monotypic (cytoplasmic) immunoglobulins	Polyclonal pattern with mixture of B and T lymphocytes; polyclonal expression of immunoglobulins

CLL, chronic lymphocytic leukaemia.

diagnostic problems regarding composite non-Hodgkin lymphomas—that is, T-cell-rich B cell lymphomas or an admixture of T cells in small B cell lymphomas. In routinely processed bone marrow tissue it may be difficult to demonstrate monoclonality, depending on the methods used, and consequently most studies have used frozen section material.^{20 33 34} The processing of bone marrow tissue in this study was restricted to easy to handle and reproducible techniques¹² without immunohistochemi-

cal limitations. A comparative study on the different methods of identifying lymphoid lesions showed an advantage of formalin fixed, decalcified, and paraffin wax embedded trephine biopsies as opposed to plastic (methyl methacrylate) or frozen sections.²² By applying a particular set of antibodies to overcome the obstacles of cross reactivity (table 1), we succeeded in showing the predominantly uniform expression of a prevailing B cell or T cell population composing these lymphoid aggre-

Figure 2 Histotopography and immunohistochemistry of malignant lymphoma infiltrates in the bone marrow. Deficient margination (A) with interstitial lymphoid cell invasion between adipocytes (Giemsa) and conspicuous spillage of B lymphocytes (L26) into the surrounding haematopoiesis in CLL (B). Tapestry-like endosteal localisation of CB-CC lymphoma infiltrates (C–E) revealing an almost uniform expression of B cell markers (C, L26). Monoclonal antibodies directed against T cells (D, UCHL-1; E, MT1) are either negative or show, in addition to very few residual B lymphocytes, some cross reactivity with a few lymphohistiocytic cells. There is paratrabecular increase in reticulin fibres (F) in these lymphoma infiltrates (CB-CC). (Magnifications: A, B, F $\times 308$; C, D, E $\times 146$.)

gates in routinely processed bone marrow specimens. This is in keeping with a recently published systematically conducted immunohistological study on paraffin embedded bone marrow biopsies which also included lymphoproliferative disorders.³⁵ Although monoclonality may present a major argument for non-Hodgkin lymphoma infiltrates versus benign lymphatic hyperplasia, this finding should be always interpreted in the context of the other features that are important in making the diagnosis, as outlined in table 4. Recently, a consistent expression of the bcl-2 protein in all

non-Hodgkin lymphoma infiltrates of the bone marrow was described, while benign lymphoid nodules were claimed to lack this antigen.³⁶ However, a critical re-evaluation of this distinctive feature showed the presence of bcl-2 in both benign as well as malignant lymphoid nodules.³⁷ For this reason, the property of bcl-2 for differentiation remains questionable.

Finally, depending on classification, comparative histology of non-Hodgkin lymphoma in lymph nodes and bone marrow showed disturbing discrepancies in several cases and thus confirmed previous studies in this field.³⁸⁻⁴⁰ In

Figure 3 Immunohistochemistry of malignant lymphoma infiltrates (LPI subtype) in the bone marrow (A, B). There is an ill defined margination (A, L26; B, MT1) and an increase in reticulin fibres in these lesions (C). Lymphoid nodules consist of B lymphocytes (D, L26), while UCHL-1 (E) shows positive staining of a few lymphohistocytes, and MT1 (F) a negative reaction. Monoclonal expression of light chains of the κ type is shown (G), contrasting negativity with an antibody directed against λ light chains (H). (Magnifications: A, B $\times 145$; C-F $\times 298$; G, H $\times 467$.)

particular, a high incidence of morphological discordance was observed with a more aggressive (large cell blastic) nodular subtype, in contrast with the findings in bone marrow.³⁹ This aspect probably involves histological progress and transformation, with a change from low to high grade malignancy which may not occur simultaneously and at the same speed in lymph node and bone marrow tissue alike.

In conclusion, a synoptic approach using several distinctive features, particularly histotopography and immunohistochemistry, presents the most promising way to differentiate between reactive and neoplastic lymphoid nodules in the bone marrow.

We are greatly indebted to Mrs B Rosenbach, Mrs M Wonschick, and Mrs P Schmitz for their excellent technical assistance.

- Rywin AM, Ortega RS, Dominguez CJ. Lymphoid nodules of bone marrow: normal and abnormal. *Blood* 1974;43:389-400.
- Bartl R, Frisch B, Burkhardt R, et al. Lymphoproliferations in the bone marrow: identification and evolution, classification and staging. *J Clin Pathol* 1984;37:233-54.
- Navone R, Valpreda M, Pich A. Lymphoid nodules and nodular lymphoid hyperplasia in bone marrow biopsies. *Acta Haematol* 1985;74:19-22.
- Faulkner-Jones BE, Howie AJ, Boughton BJ, et al. Lymphoid aggregates in bone marrow: study of eventual outcome. *J Clin Pathol* 1988;41:768-75.
- McKenna RW, Hernandez JA. Bone marrow in malignant lymphoma. *Hematol Oncol Clin North Am* 1988;2:617-35.
- Salisbury JR, Deverell MH, Cookson MJ. Three-dimensional reconstruction of benign lymphoid aggregates in bone marrow trephines. *J Pathol* 1996;178:447-50.
- Manoharan A, Catovsky D, Clein P, et al. Simultaneous or spontaneous occurrence of lympho- and myeloproliferative disorders: a report of four cases. *Br J Haematol* 1981;48:111-16.
- Cervantes F, Pereira A, Marti JM, et al. Bone marrow lymphoid nodules in myeloproliferative disorders: association with the non-myelocytic phases of idiopathic myelofibrosis and immunological significance. *Br J Haematol* 1988;70:279-82.
- Franco V, Florena AM, Aragona F, et al. Immunohistochemical evaluation of bone marrow lymphoid nodules in chronic myeloproliferative disorders. *Virchows Arch A Pathol Anat* 1991;419:261-6.
- Bartl R, Frisch B, Wilmanns W. Potential of bone marrow biopsy in chronic myeloproliferative disorders (MPD). *Eur J Haematol* 1993;50:41-52.
- Stansfeld AG, Diebold J, Kapanci Y, et al. Updated Kiel classification for lymphomas. *Lancet* 1988;i:292-3.
- Schaefer HE. How to fix, decalcify and stain paraffin-embedded bone marrow biopsies. In: Lennert K, Huebner K, eds. *Pathology of the bone marrow*. Stuttgart: Fischer, 1984:6-9.
- Cordell JL, Falini B, Erber WN, et al. Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). *J Histochem Cytochem* 1984;32:219-29.
- Erber WN. Human leucocyte differentiation antigens: review of the CD nomenclature. *Pathology* 1990;22:61-9.
- Thiele J, Arenz B, Klein H, et al. Differentiation of plasma cell infiltrates in the bone marrow. A clinicopathological study on 80 patients including immunohistochemistry and morphometry. *Virchows Arch A Pathol Anat* 1988;412:553-62.
- Bartl R, Frisch B, Ketter G, et al. Assessment of bone marrow histology in the malignant lymphomas (non-Hodgkin's): correlation with clinical factors for diagnosis, prognosis, classification, and staging. *Br J Haematol* 1982;51:511-30.
- Vykoupil KF, Georgii A. Non-Hodgkin's lymphomas in bone marrow: diagnosis according to Kiel classification and their growth patterns and relations to survival. In: Lennert K, Huebner K, eds. *Pathology of the bone marrow*. Stuttgart: Fischer, 1984:339-46.
- Foucar F, McKenna RW, Frizzera G, et al. Bone marrow and blood involvement by lymphoma in relationship to the Lukes-Collins classification. *Cancer* 1982;49:888-97.
- Bennett JM, Cain KC, Glick JH, et al. The significance of bone marrow involvement in non-Hodgkin's lymphoma: the eastern cooperative oncology group experience. *J Clin Oncol* 1986;4:1462-9.
- Thaler J, Dietze O, Denz H, et al. Bone marrow diagnosis in lymphoproliferative disorders: comparison of results obtained from conventional histomorphology and immunohistology. *Histopathology* 1991;18:495-504.
- Lambertenghi-Delilieri G, Annaloro C, Soligo D, et al. Incidence and histological features of bone marrow involvement in malignant lymphomas. *Ann Hematol* 1992;65:61-5.
- Schmid C, Isaacson PG. Bone marrow trephine biopsy in lymphoproliferative disease. *J Clin Pathol* 1992;45:745-50.
- Bartl R, Frisch B, Burkhardt R, et al. Assessment of bone marrow histology in Hodgkin's disease: correlation with clinical factors. *Br J Haematol* 1982;51:345-60.
- Han T, Barcos M, Emrich L, et al. Bone marrow infiltration patterns and their prognostic significance in chronic lymphocytic leukemia: correlations with clinical, immunologic, phenotypic, and cytogenetic data. *J Clin Oncol* 1984;2:562-70.
- Rozman C, Montserrat E, Rodríguez-Fernández JM, et al. Bone marrow histologic pattern—the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. *Blood* 1984;64:642-8.
- Pangalis GA, Roussou PA, Kittas C, et al. B-chronic lymphocytic leukemia. Prognostic implication of bone marrow histology in 120 patients—experience from a single hematology unit. *Cancer* 1987;59:767-71.
- Montserrat E, Rozman C. Bone marrow biopsy in chronic lymphocytic leukemia: a review of its prognostic importance. *Blood Cells* 1987;12:315-26.
- Frisch B, Bartl R. Histologic classification and staging of chronic lymphocytic leukemia. A retrospective and prospective study of 503 cases. *Acta Haematol* 1988;79:140-52.
- Frisch B, Bartl R, Goebel FD. Bone marrow manifestations in the acquired immune deficiency syndrome (AIDS). A study of 40 patients and review of the literature. *Hematol Rev* 1989;3:177-86.
- Harris CE, Biggs JC, Concannon AJ, et al. Peripheral blood and bone marrow findings in patients with acquired immune deficiency syndrome. *Pathology* 1990;22:206-11.
- Karcher DS, Frost AR. The bone marrow in human immunodeficiency virus (HIV)-related disease. *Am J Clin Pathol* 1991;95:63-71.
- Thiele J, Langohr J, Skorupka M, et al. Reticulin fibre content of bone marrow infiltrates of malignant non-Hodgkin's lymphomas (B-cell type, low malignancy)—a morphometric evaluation before and after therapy. *Virchows Arch A Pathol Anat* 1990;417:485-92.
- Kronland R, Grogan T, Spier C, et al. Immunotopographic assessment of lymphoid and plasma cell malignancies in the bone marrow. *Hum Pathol* 1985;16:1247-54.
- Pizzolo G, Chilosi M, Certo GL, et al. Immuno-histological analysis of bone marrow involvement in lymphoproliferative disorders. *Br J Haematol* 1992;50:95-100.
- Pileri SA, Roncador G, Ceccarelli C, et al. Immunohistochemistry of bone marrow biopsy. *Leukemia Lymphoma* 1997;26(suppl 1):69-75.
- Ben-Ezra JM, King BE, Harris AC, et al. Staining for bcl-2 protein helps to distinguish benign from malignant lymphoid aggregates in bone marrow biopsies. *Mod Pathol* 1994;7:560-64.
- Fakan F, Skálava A, Kuntscherová J. Expression of bcl-2 protein in distinguishing benign from malignant lymphoid aggregates in bone marrow biopsies. *Gen Diagn Pathol* 1995;96:141:359-63.
- Bartl R, Hansmann ML, Frisch B, et al. Comparative histology of malignant lymphomas in lymph node and bone marrow. *Br J Haematol* 1988;69:229-37.
- Conlan MG, Bast M, Armitage JO, et al. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. *J Clin Oncol* 1990;8:1163-72.
- Kluin PM, van Krieken JH, Kleiverda D, et al. Discordant morphologic characteristics of B-cell lymphomas in bone marrow and lymph node biopsies. *Am J Clin Pathol* 1990;94:59-66.